Delivery Order SPE2DB20D3103-SPE2DB22FM1B2
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,781.72 firm fixed-price delivery order is for the supply of GONAL-F RFF REDI-JECT 900 UNIT 1.5ML, a specialty medication. The contract has an ultimate completion date of January 20, 2022 and was awarded on January 19, 2022. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant...
- This federal contract award, valued at $16,286.10, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award is for the delivery of GONAL-F RFF REDI-JECT 450 UNIT 0.75ML medical supplies, with a performance period through May 10, 2024. This is a delivery order contract with a firm fixed price pricing type. The contract has no set-aside designation, indicating open competition....
- This federal contract award, valued at $6,930.70, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of Gonal-F RFF Redi-Ject 900 unit 1.5ml, a pharmaceutical product, with a completion date of June 5, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth up to $999,999,999.00 through December...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $11,734.62, is for the delivery of GONAL-F RFF REDI-JECT 450 UNIT 0.75ML medical supplies. It is a firm fixed-price delivery order contract with a completion date of February 4, 2025. The contract is not designated with any set-aside requirements, indicating open competition....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,646.22 firm fixed-price delivery order is for the supply of GONAL-F RFF REDI-JECT 450 UNIT 0.75ML pharmaceutical product. The contract has a performance period through March 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,852.82 firm fixed-price contract is for the supply of GONAL-F RFF REDI-JECT 300 UNIT 0.5ML, a prescription medication. The contract has an ultimate completion date of March 24, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,481.11 firm fixed price delivery order is for the supply of GONAL-F RFF REDI-JECT 900 UNIT 1.5ML, a specialty pharmaceutical product. The award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,362,463 units of GONAL-F RFF REDI-JECT 450 unit 0.75ML pharmaceuticals. The $7,797.00 contract has a completion date of January 19, 2024. Amerisourcebergen Drug Corp is a prime contractor that provides a range of pharmaceutical products and medical supplies to support DLA programs. This delivery...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GONAL-F RFF REDI-JECT 900 UNIT 1.5ML, a pharmaceutical product, with a ceiling value of $47,359.24. The contract is a firm fixed-price delivery order with a completion date of June 16, 2025. This award is not designated as a set-aside contract, indicating open competition....
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $101,892.98, is for the delivery of Gonal-F RFF Redi-Ject 900 Unit 1.5ML medical supplies. The contract is a Firm Fixed Price delivery order with a performance period extending to February 3, 2025. Amerisourcebergen Drug Corp is a for-profit organization registered in the...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB22FM1B2Delivery Order
This federal contract award, valued at $5,728.44, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a Delivery Order for the supply of GONAL-F RFF REDI-JECT 900 UNIT 1.5ML, a pharmaceutical product. The contract has an ultimate completion date of December 29, 2021 and is a Firm Fixed Price arrangement. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is also registered in the System for Award Management (SAM.gov). This contract is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.7k | 12/28/21 |